Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract

British Journal of Ophthalmology

Volumn 91, Issue 5, 2007, Pages 629-632

  Cantor, Louis B ^a,b   Hoop, Joni ^b   Wudunn, Darrell ^b   Yung, Chi Wah ^b   Catoira, Yara ^b   Valluri, Shailaja ^b   Cortes, Arnold ^b   Acheampong, Andrew ^c   Woodward, David F ^c   Wheeler, Larry A ^c  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; PLACEBO;

AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

AMIDES; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CATARACT; CATARACT EXTRACTION; CLOPROSTENOL; DOUBLE-BLIND METHOD; HUMANS; LIPIDS; PROSPECTIVE STUDIES;

EID: 34248193276     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.110155     Document Type: Article

References (18)

1. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of Xalatan: the Proctor lecture. Invest Ophthalmol Vis Sci 2001;42:1134-45.
2. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003;305:772-85.
3. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002;47(Suppl 1):S34-40.
4. Davies SS, Ju WK, Neufeld AH, et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther 2003;19:45-54.
5. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19-24.
6. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(Suppl 1):S6-12.
7. Camras CB, Toris CB, Sjoquist B, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 2004;111:2193- 8.
8. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003;44:71 5-21.
9. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-15.
10. Sharif NA, Crider JY, Husain S, et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther 2003;19:437-55.
11. Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004;111:1658-62.
12. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 2001;45(Suppl 4):S347-51.
13. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
14. Parrish R, Palmberg P, Sheu W-P, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2003;135:688-703.
15. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther 2004;21:247-62.
16. Sharif NA, Xu SX, Williams GW, et al. Pharmacoloay of [3H]prostaglandin El/ [3H]prostaqlandin E2 and [3H]prostaglandin F2alpna binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data. J Pharmacol Exp Ther 1998;286:1094-102.
17. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001;45(Suppl 4):S337-45.
18. Sjoquist B, Johansson A, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography, Glaucoma research laboratories. Arzneimittelforschung 1999;49:240-9.